Parallel FDA and CMS review of new technologies can save manufacturers research costs and reduce the time between FDA approval and national Medicare coverage of a new technology, according to at least one of the companies that has participated in the program.
The two agencies formally launched a pilot program for parallel review in 2011, opening up a collaborative effort that allows CMS to begin considering a national Medicare coverage policy for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?